Ionis Pharmaceuticals, Inc. (IONS)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
SPINRAZA Royalties Revenue	221.90M	216.10M	Log In	Log In	Log In	Upgrade
WAINUA Royalties Revenue	43.00M	20.20M	Log In	Log In	Log In	Upgrade
TEGSEDI and WAYLIVRA Revenue	36.90M	34.20M	Log In	Log In	Log In	Upgrade
Commercial Licensing and Other Royalty Revenue	78.60M	22.60M	Log In	Log In	Log In	Upgrade
Total Commercial Revenue	380.40M	293.10M	Log In	Log In	Log In	Upgrade
Amortization from Upfront Payments Revenue	-	131.40M	Log In	Log In	Log In	Upgrade
Milestone Payments Revenue	-	106.40M	Log In	Log In	Log In	Upgrade
R&D License Fees Revenue	-	71.30M	Log In	Log In	Log In	Upgrade
Other R&D Services Revenue	-	23.50M	Log In	Log In	Log In	Upgrade
Collaborative Agreement Revenue	510.00M	332.60M	Log In	Log In	Log In	Upgrade
Eplontersen Joint Development Revenue	76.40M	79.40M	Log In	Log In	Log In	Upgrade
Total R&D Revenue	586.40M	412.00M	Log In	Log In	Log In	Upgrade
Revenue (Other)	-629.24M	-432.16M	Log In	Log In	Log In	Upgrade
Revenue (Total)	966.96M	705.14M	Log In	Log In	Log In	Upgrade

Updated Oct 29, 2025. Data Source: Fiscal.ai.